Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTRABECTEDIN (trabectedin) by Johnson & Johnson is alkylating activity [moa]. Approved for alkylating drug [epc].
Drug data last refreshed 1mo ago
Alkylating Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Worked on TRABECTEDIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo